(A) Recombinant MYC (wild-type [WT], 4A, or VP16 HBM):MAX dimers used in these assays. Dimers were separated by SDS-PAGE alongside a BSA standard and stained using Coomassie Brilliant Blue. (B) Electrophoretic mobility shift assay (EMSA) using recombinant MYC:MAX and MAX:MAX dimers incubated with a biotinylated E-box probe (5′-GCTCAGGGACCACGTGGTCGGGGATC-3′). Binding reactions were conducted with or without 100-fold excess of unlabeled specific (as above) or nonspecific (5′-GCTCAGGGACCAGCTGGTCGGGGATC-3′) competitors. (C and D) Heatmap of the combined average normalized peak intensity in 100 bp bins for all HCF-1N (C) or MYC-HA (D) ChIP-Seq peaks that were within ±2 kb of a TSS, and scaled across each of the cell lines. For clarity in (D), some low-signal data points are excluded. (E) Example IGV screenshots of regions that had significant changes for MYC-HA by ChIP-seq. Asterisks mark the peaks that were significantly changed compared to WT. (F) ChIP, using anti-HCF-1N antibody, was performed on parental or switchable Ramos cells treated for 24 hr with 20 nM 4-OHT. Enrichment of genomic DNA was monitored by qPCR using primers that amplify across peaks. EIF4G3 and HBB are negative loci for HCF-1N. ChIP efficiency was measured based on the percent recovery from input DNA. Shown are the mean and standard error for three biological replicates.